The present disclosure provides a pharmaceutical composition for treating or preventing cancer, comprising inhibitors of KIRREL3, CNTN4 and/or CD351. In addition, the present disclosure provides a pharmaceutical composition for immune-enhancing, comprising inhibitors of KIRREL3, CNTN4 and/or CD351. Furthermore, the present disclosure provides a method of screening of anti-cancer agent using KIRREL3, CNTN4 and/or CD351, and a method of providing information necessary for analysis of cancer prognosis using KIRREL3, CNTN4 and/or CD351.

Disclosed herein anti-TNF therapy companion diagnostics (e.g., a predictive biomarker panel) for management of Crohn's Disease (CD). The disclosed companion diagnostics may be used to identify an appropriate treatment for a patient, and includes, for example, in vitro diagnostic tests or devices that provide information for the use of an anti-TNF therapy. The disclosed methods may be used, in certain aspects, for the identification of patients likely to respond, or as not likely to respond to an anti-TNF agent. The use of the disclosed methods may allow for dose determination, discontinuation, or the administration of combinations of therapeutic agents.

The use of differentiation marker CD89 for the detection of cellular reservoirs of a mammalian immunodeficiency virus. Also the use of the differentiation marker CD89 for making a prognosis, diagnosing a remission, and evaluating the efficacy of treatment of the mammalian immunodeficiency. A multi-specific antibody that recognizes both at least one epitope of CD89 and at least one characteristic of the lymphocyte cells, a composition including the antibody, and the use of the antibody for treatment.

The present inventors discovered that incorporating an Fc region and an antigen-binding domain whose antigen-binding activity varies depending on ion concentration into an antigen-binding molecule that binds to an aggregate-forming antigen produces an antigen-binding molecule that can preferentially clear protein aggregates in comparison to protein monomers from plasma. Use of antigen-binding molecules of the present invention allows various diseases stemming from target tissues to be treated target-tissue-specifically. Use of antigen-binding molecules of the present invention enables treatment of diseases caused by protein aggregates.

The present invention relates to methods and apparatuses for monitoring the state of health of dairy cows, in particular of entire dairy herds. The method is based on analysing the haptoglobin (HP) biomarker and part of the polymeric immunoglobulin receptor (PIGR), the secretory component (Secretory Component, SC), in a milk sample. In particular, the claimed method and apparatus of the invention make it possible to diagnose mastitis or systemic diseases which occur outside the udder on the basis of the protein biomarker described here. The invention therefore makes it possible to regularly monitor the general state of health of a dairy herd. The present invention relates to non-invasive diagnostic methods and to apparatuses and diagnostic kits for carrying out these methods.

This disclosure provides for compositions and methods that can be used to predict an individuals risk for experiencing a cardiovascular event following a surgical procedure (e.g., a non-cardiac surgical procedure).

Methods of identifying monocyte subsets in a sample are provided. Aspects of the methods include assaying the sample to obtain relative expression level data for each of CD14, CD16, and CD192 (CCR2) and quantitative expression level data for HLA-DR; and employing the obtained data to identify monocyte subsets in the sample. Also provided are compositions and kits for practicing embodiments of the invention. The methods and compositions find use in a variety of different applications, including therapeutic applications.

This disclosure relates to methods and composition for assessing conditions related to immune complex (IC)-mediated neutrophil activation and interventions to address the conditions. The disclosed methods include detecting the presence of ICs in a biological sample, and/or detecting the formation of neutrophil extracellular traps (NETs) in a biological sample. Other disclosed methods include detecting the modification or cleavage of FcgRIIA on circulating cells obtained from a patient. The assays and related compositions can identify patients with a severe phenotype and have the capacity to predict future disease flare and disease progression allowing for early preventive treatment and monitoring. The disclosure also provides compositions and kits to support performance of the disclosed methods.

In accord with the present invention, the fertility quality of an ejaculate can be determined by assaying sperm, in aliquots of the ejaculate or of an ejaculate produced previously by the same male, at intervals over a period of time. Fertility quality is determined by the number of times the level of expression of a marker on the sperm goes through a maximum level of expression during the period of time and if desired by sperm state and fertilization procedure used. The marker should be capable of correlation with the level of Fc receptor (FcR) expression on the sperm. The fertility quality of the ejaculate is related to the number of times a maximum level of expression is reached.

Methods of treating a tumor in a subject and methods of determining a treatment regimen for a subject with a tumor are provided herein. In exemplary aspects, the methods comprise measuring the level of expression of immunoglobulin, FCGR2B, a gene listed in Table 4, or a combination thereof. In exemplary aspects, the subject is a subject from which a sample was obtained, wherein the level of immunoglobulin, FCGR2B, a gene listed in Table 4, or a combination thereof, has been measured from the sample. Related kits, computer readable-storage media, systems, and methods implemented by a processor in a computer are further provided.